Related Experiment Video

Updated: May 18, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

[Is there still a place for a dual blockade of the renin-angiotensin system in 2012?]

J-M Krzesinski1, A J Scheen

  • 1Service de néphrologie-dialyse-hypertension, Département de médecine, Université de Liège, CHU Sart-Tilman, 4000 Liège, Belgique. jm.krzesinski@chu.ulg.ac.be

Revue Medicale Suisse
|September 20, 2012
PubMed

Insights

Blocking the renin-angiotensin system (RAS) helps patients with diabetes and hypertension. Dual RAS blockade offers no additional cardiorenal protection and increases risks, unlike single blockade, necessitating careful medical supervision for alternative strategies.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Context:

  • Renin-angiotensin system (RAS) blockade is crucial for managing cardiovascular and renal diseases linked to diabetes, hypertension, and atherosclerosis.
  • Observational studies suggested dual RAS blockade for enhanced cardiorenal protection.
  • Recent trials question dual blockade's superiority over monotherapy, highlighting increased risks of renal complications and hyperkalemia.

Purpose:

  • To evaluate the efficacy and safety of dual renin-angiotensin system (RAS) blockade compared to monotherapy.
  • To explore alternative strategies for reducing residual cardiovascular and renal risk in patients with RAS-related conditions.

Summary:

  • Dual RAS blockade did not demonstrate superior cardiorenal protection compared to single blockade in recent randomized controlled trials.
  • Dual blockade was associated with a higher incidence of renal complications and hyperkalemia.
  • Alternative approaches like intensified low-salt diet, supraphysiological monotherapy doses, or aldosterone antagonists may be considered but require strict medical supervision due to risks of hypotension and renal insufficiency.

Impact:

  • Findings challenge the established benefits of dual RAS blockade, prompting a re-evaluation of treatment strategies.
  • Highlights the need for individualized treatment approaches to minimize residual risk while avoiding adverse events.
  • Emphasizes the importance of close medical monitoring for patients undergoing intensified RAS inhibition or alternative therapies.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...